Navigation Links
Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers
Date:3/5/2009

anyladenine) in improving the clinical signs and symptoms of rosacea. Subjects were evaluated through physician assessments of inflammatory lesion count (papules and pustules), severity of erythema (redness) and telangiectasia (spider veins) and overall clinical improvement, as well as through patient assessments of signs and symptoms of rosacea and skin tolerance.

After 48 weeks, there was overall clinical improvement in 80% of subjects, including reduction of erythema and papules. The investigators saw continual, statistically significant mean improvement with Pyratine XR(TM) treatment, including a 90% improvement in lesions, 45% improvement in erythema and a 28% improvement in telangiectasia. The product was well tolerated, and in an earlier assessment of 24 patients, there was a 41% mean improvement in skin dryness as early as week four, with results continuing to improve over the 48-week period. Pyratine XR(TM) produced a significant improvement in skin barrier function at weeks 4 through 48 as measured by a decrease in water loss from the skin.

According to the National Rosacea Society, more than 14 million Americans have rosacea, yet only a small fraction are being treated. The chronic skin disease can affect adults and children of any skin type. While the cause is unknown and there is no cure, scientific advancements are now offering rosacea sufferers hope and a way to control the signs and symptoms of this potentially life-disruptive disorder.

For more information, please visit Senetek at Booth #5736 or online at www.PyratineXR.com.

About Senetek PLC

Senetek PLC (OTCBB: SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with b
'/>"/>

SOURCE Senetek PLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dr. Mark Nestor Presents on Pyratine-6(TM) at the South Beach Symposium
2. Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology
3. Senetek PLC in Dispute With Marketer of Pyratine-6(TM)
4. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
5. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
6. Video: Keppra XR(TM) Approved in the U.S.
7. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
8. Novozymes Launches Enzyme to Reduce Acrylamide in Food
9. Enova Medical Launches Exos Corporation
10. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
11. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... TEL AVIV, Israel , July 23, 2014 ... Ltd ., a portfolio company of Trendlines ... with one of Israel,s ... (Logo: http://photos.prnewswire.com/prnh/20140121/666259-a) , Valentis,s technology combines ... from plant pulp waste, with additional nanoparticles to ...
(Date:7/23/2014)... BRUSSELS , July 23, 2014 regulated ... its research and development pipeline with positive topline ... brivaracetam . This study was designed to evaluate ... (100 and 200 mg/day, without titration) compared to ... patients with partial-onset seizures, not fully controlled despite ...
(Date:7/23/2014)... 23, 2014  Sofinnova Ventures, a Menlo ... closing of Sofinnova Venture Partners IX, L.P. at the ... the initial fund target of $425 million. ... companies. Consistent with recent funds, SVP IX will provide ... programs, along with select investments in earlier stage opportunities. ...
(Date:7/23/2014)... 23, 2014 OncLive® is pleased ... has joined its Strategic Alliance Partnership program. ... program, UNC Lineberger will have the opportunity to ... of its cutting-edge research initiatives, community-directed cancer prevention ... will work with OncLive to educate their peers ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
... Sinobiopharma Pharmaceutical Group (OTC Bulletin Board: SNBP) is ... Tan as Director of Marketing.Ms. Tan joins Sinobiopharma ... as a China-based Unit Marketing Director for Organon, ... Organon, Ms. Tan held senior marketing management roles ...
... 8 Biopharmaceutical company Kiadis,Pharma reported preliminary ... mismatched bone marrow transplantations. Data was presented ... Roy during the prestigious,Presidential Symposium at the ... Goteborg, Sweden, on Monday, March 30, 2009. ...
... Inc. announced today that it has entered into ... NYSE: SNY ), providing the global ... platform for the research, development and commercialization of ... (ADCC). "We are extremely pleased about our partnership ...
Cached Biology Technology:Sinobiopharma, Inc. Appoints New Director of Marketing 2Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations 2BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis 2
(Date:7/23/2014)... local and national governments struggle to deal with ever-growing ... refining the picture of just how much there is ... ACS journal Environmental Science & Technology , their ... developed countries discard floods into just seven developing countries ... who live there. , Knut Breivik and colleagues note ...
(Date:7/23/2014)... the International Journal of Fuzzy Systems ( ... Systems Association (TFSA). The cooperation will allow the journal ... fuzzy research., The International Journal of Fuzzy Systems ... with the theory, design and application of fuzzy systems, ... ranging from hardware to software. Launched in 1999, the ...
(Date:7/23/2014)... is available in German . ... modalities for orientation, some of which might be very ... the polarization pattern produced by sunlight in the atmosphere ... Max Planck Institute for Ornithology in Seewiesen, Germany, and ... that a night active mammal, the greater mouse-eared bat, ...
Breaking Biology News(10 mins):Bats use the evening sky's polarization pattern for orientation 2
... Sobrado, assistant professor of biochemistry at Virginia Tech, ... Prize, administered by the Ministry of Science and ... research is "a significant contribution to the diagnosis ... to a release distributed my MICIT. Sobrado, ...
... may have just provided the medical community a new way ... blocks of life forms and functions. University of Central ... program to analyze RNA motifs the subunits that make ... three building blocks of life along with DNA and proteins. ...
... in mice suggests a novel strategy for treating damaged ... approach potentially could improve cardiac function, minimize scar size, ... and avoid the risk of tissue rejection. In ... ONE , ( http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0030329 ) the researchers isolated and ...
Cached Biology News:Contributions to diagnosis, treatment of tropical diseases recognized 2Stem cell study in mice offers hope for treating heart attack patients 2Stem cell study in mice offers hope for treating heart attack patients 3
...
... is used as an internal standard for ... dilution mass spectrometry. 5-OxoETE is a polyunsaturated ... 5-HETE in human neutrophils. It stimulates cytosolic ... of 2 nM. 5-OxoETE selectively stimulates the ...
... Scalable SNPstream System Delivers 4,600 to ... GenomeLab SNPstream Genotyping System is capable of ... per day. Part of the GenomeLab family ... can process up to 48 SNPs in ...
... are a mixture of Strep•Tag® II fusion ... The markers provide precise size references for ... Coomassie blue. Because each of the proteins ... can also be detected by the Strep•Tag ...
Biology Products: